KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBIT Margin (2020 - 2025)

Recursion Pharmaceuticals filings provide 6 years of EBIT Margin readings, the most recent being 304.84% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 373757.0% to 304.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 867.87%, a 5377.0% decrease, with the full-year FY2025 number at 867.87%, down 5377.0% from a year prior.
  • EBIT Margin hit 304.84% in Q4 2025 for Recursion Pharmaceuticals, up from 3327.57% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 304.84% in Q4 2025 to a low of 4042.41% in Q4 2024.
  • Median EBIT Margin over the past 5 years was 912.56% (2023), compared with a mean of 1242.91%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 2938181bps in 2021 and later crashed -313405bps in 2024.
  • Recursion Pharmaceuticals' EBIT Margin stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then crashed by -104bps to 908.36% in 2023, then tumbled by -345bps to 4042.41% in 2024, then soared by 92bps to 304.84% in 2025.
  • The last three reported values for EBIT Margin were 304.84% (Q4 2025), 3327.57% (Q3 2025), and 916.75% (Q2 2025) per Business Quant data.